The use of decentralized trials has surged during COVID-19. CRO (contract research organization) Icon is set to acquire PRA Health Sciences. This will bring big changes to CROs and Icon is expected to direct anincreasing number of decentralized trials.
“Icon, the Dublin-based CRO, will acquire PRA Health Sciences for $12 billion in a move that will shake up the highest rungs of a fragmented market. The merger would combine the 5th- and 6th-largest CROs by 2020 revenue, according to Icon, and the merger will set the newco up to be the second-largest global CRO behind only IQVIA.” Read more here.
(Source: Max Gelman, Endpoints News, 1/24/21)